Every material Form 8-K Supernus Pharmaceuticals filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Supernus reported third-quarter 2025 total revenue of $192.1 million, up 9% from a year earlier, but posted a net loss of $45.1 million, or $0.80 per diluted share, compared with net earnings of $38.5 million a year earlier. The company raised its full-year 2025 revenue guidance and narrowed its operating loss guidance, but said supplier constraints are forcing it to pause new ONAPGO patient deliveries while it rebuilds inventory.
Total revenue was $192.1 million for the quarter, up 9%; combined revenue of the four growth products rose 52% to $149.2 million.
Net loss was $45.1 million ($0.80 per diluted share), driven by higher SG&A that included approximately $70.0 million of Sage acquisition-related costs.
Full-year 2025 total revenue guidance was raised to $685 million to $705 million from $670 million to $700 million; GAAP operating loss guidance is now $(65) million to $(75) million, versus $(70) million to $(80) million previously.
Supernus is pausing delivery to patients who have not yet started ONAPGO and will provide timely updates on resolving the supply constraint.
Supernus Pharmaceuticals announced it will report third quarter 2025 financial and business results after the market closes on Tuesday, November 4, 2025, and host a conference call and webcast that day at 4:30 p.m. ET. The announcement is a scheduling notice and contains no financial results, so it gives shareholders no new information on performance.
Third quarter 2025 results expected after market close on Tuesday, November 4, 2025
Conference call and webcast scheduled for November 4, 2025 at 4:30 p.m. ET
CEO Jack Khattar and CFO Tim Dec will present the results on the call
Supernus reported second-quarter 2025 total revenues of $165.5 million, down 2% from $168.3 million a year earlier, while diluted earnings per share rose to $0.40 from $0.36 and net earnings were $22.5 million. It raised full-year 2025 revenue guidance to $670 million-$700 million and moved its GAAP operating earnings guidance to a loss of $70 million-$80 million, citing the Sage Therapeutics acquisition completed July 31, 2025. For shareholders, quarterly profit improved, but revenue slipped and the GAAP operating outlook worsened.
Q2 2025 total revenues were $165.5 million, versus $168.3 million in Q2 2024; Qelbree net sales rose 31% to $77.6 million.
Q2 2025 net earnings were $22.5 million, or $0.40 per diluted share, versus $0.36 a year earlier; six-month diluted EPS was $0.19 versus $0.36.
Full-year 2025 total revenue guidance is $670 million-$700 million, up from $600 million-$630 million.
Full-year 2025 GAAP operating earnings (loss) guidance is $(70) million to $(80) million, down from $(15) million to $10 million.
Supernus Pharmaceuticals named Frank Mottola, previously its Senior Vice President, Quality, GMP Operations and IT, as Chief Technical Operations Officer effective June 16, 2025. His annual base salary rose from $392,500 to $412,500 and his 2025 bonus target rose from 35% to 40% of base salary.
Frank Mottola appointed Chief Technical Operations Officer, effective June 16, 2025
Annual base salary increased from $392,500 to $412,500
2025 bonus target increased from 35% to 40% of base salary
Board approved the appointment and pay changes on the Compensation Committee's May 30, 2025 recommendation
Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics after 36,313,509 Sage shares, about 58% of those outstanding, were tendered by the July 30, 2025 expiration of the offer. Sage is now a wholly owned subsidiary, and the Sage shares will be delisted from the Nasdaq Global Market. The total cash consideration excluding contingent value rights is approximately $561 million, and the CVRs add up to $3.50 per share in potential future payments tied to milestones that may never be reached.
Offer price was $8.50 per Sage share in cash plus one contingent value right worth up to $3.50 per share
Aggregate consideration is approximately $561 million, excluding amounts that may be payable under the CVRs
Maximum total CVR payments are approximately $234 million, with milestones tied to ZURZUVAE net sales and a Japan approval by June 30, 2026
The merger closed on July 31, 2025 without a Sage stockholder vote, and the Sage shares will be delisted from the Nasdaq Global Market
Supernus Pharmaceuticals said it will report second quarter 2025 financial and business results after the market closes on Tuesday, August 5, 2025. The filing contains no financial results; it sets the date and format for the release and the earnings call.
Results expected after market close on Tuesday, August 5, 2025
Conference call and webcast at 4:30 p.m. ET on August 5, 2025, hosted by CEO Jack Khattar and CFO Tim Dec
Live webcast on the investor relations website at www.supernus.com/investors; replay available for 60 days after the call
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Supernus Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →